Company: RCUS
Filing Date: 2025-10-31
Form Type: 424B5
Source: 0001193125-25-260836
Chunk: 8

Company: Arcus Biosciences, Inc.
Filing Date: 2025-10-31
Form: 424B5
Chunk 8
---
 |

| • |     | Any investigational products for which we intend to seek approval as biologic products may face competition 
 sooner than anticipated.                                                                                    |

| • |     | We are currently party to several in-license agreements under which we                                                                                                                                                                                  
 acquired rights to use, develop, manufacture and/or commercialize certain of our investigational products. If we breach our obligations under these agreements, we may be required to pay damages, lose our rights to these investigational products or 
 both, which would adversely affect our business and prospects.                                                                                                                                                                                          |

| • |     | If we are unable to obtain and maintain sufficient intellectual property protection for our investigational                                                                                                                                           
 products, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be 
 adversely affected.                                                                                                                                                                                                                                   |

| • |     | We may become involved in lawsuits alleging that we have infringed the intellectual property rights of third                                                                                                                
 parties or to protect or enforce our patents or other intellectual property, which litigation could be expensive, time consuming and adversely affect our ability to develop or commercialize our investigational products. |

| • |     | Changes in patent law in the United States and other jurisdictions could diminish the value of patents in 
 general, thereby impairing our ability to protect our investigational products.                           |

| • |     | We may rely on trade secret and proprietary know-how which can be                                                                                                
 difficult to trace and enforce, and if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. |

| • |     | We expect to expand our business operations, and as a result, we may encounter difficulties in managing our 
 growth, which could disrupt our operations.                                                                 |

| • |     | We face substantial competition, which may result in others discovering, developing or commercializing products                                                                                               
 more quickly or marketing them more successfully than us. If their investigational products are shown to be safer or more effective than ours, then our commercial opportunity will be reduced or eliminated. |

| • |     | Our internal information technology systems, and those of our third-party contract research organizations and                                                                                                                                 
 other third parties upon which we rely, are subject to failure, security breaches and other disruptions, which could result in a material disruption of our investigational products’ development programs, jeopardize sensitive information, 
 prevent us from accessing critical information or result in a loss of our assets,